Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fareed

Showing results (361-370 of 384) with videos related to

Pageof 39
Sort By:
Thrombosis Research|November 26, 1999
Laboratory monitoring of pentasaccharide in a dog model of hemodialysisD A Hoppensteadt, W P Jeske, J M Walenga, et al.
Neurobiology of Aging|January 5, 2002
Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25-35)-induced abnormal tau protein immunoreactivity in rat brainB Dudas, U Cornelli, J M Lee, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulationJ Fareed, J M Walenga, D A Hoppensteadt, et al.
Acta Chirurgica Scandinavica. Supplementum|January 1, 1990
Pharmacologic profile of a low molecular weight heparin (enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effectsJ Fareed, J M Walenga, M Lassen, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial diseaseA Strano, J Fareed, C Sabbá, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodiesS Ahmad, W P Jeske, J M Walenga, et al.
Thrombosis Research|July 1, 1991
Components of coagulation and fibrinolysis during thrombosis prophylaxis with a low molecular weight heparin (Enoxaparin) versus Dextran 70 in hip arthroplastyL C Borris, J V Sørensen, M R Lassen, et al.
Journal of Cardiac Surgery|January 28, 2005
Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularizationO Iqbal, M Tobu, S Aziz, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 22, 2004
Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in ratsThyyar M Ravindranath, Masakatsu Goto, Muzaffer Demir, et al.
Journal of Thrombosis and Haemostasis : JTH|March 28, 2009
Recommendations on biosimilar low-molecular-weight heparinsJ Harenberg, A Kakkar, D Bergqvist, et al.
Pageof 39

Showing results (361-370 of 384) with videos related to

Sort By:
Pageof 39
Thrombosis Research|November 26, 1999
Laboratory monitoring of pentasaccharide in a dog model of hemodialysisD A Hoppensteadt, W P Jeske, J M Walenga, et al.
Neurobiology of Aging|January 5, 2002
Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25-35)-induced abnormal tau protein immunoreactivity in rat brainB Dudas, U Cornelli, J M Lee, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulationJ Fareed, J M Walenga, D A Hoppensteadt, et al.
Acta Chirurgica Scandinavica. Supplementum|January 1, 1990
Pharmacologic profile of a low molecular weight heparin (enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effectsJ Fareed, J M Walenga, M Lassen, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial diseaseA Strano, J Fareed, C Sabbá, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodiesS Ahmad, W P Jeske, J M Walenga, et al.
Thrombosis Research|July 1, 1991
Components of coagulation and fibrinolysis during thrombosis prophylaxis with a low molecular weight heparin (Enoxaparin) versus Dextran 70 in hip arthroplastyL C Borris, J V Sørensen, M R Lassen, et al.
Journal of Cardiac Surgery|January 28, 2005
Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularizationO Iqbal, M Tobu, S Aziz, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 22, 2004
Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in ratsThyyar M Ravindranath, Masakatsu Goto, Muzaffer Demir, et al.
Journal of Thrombosis and Haemostasis : JTH|March 28, 2009
Recommendations on biosimilar low-molecular-weight heparinsJ Harenberg, A Kakkar, D Bergqvist, et al.
Pageof 39